All In Biotech

Drug Trial Radar · NCT07589569

An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer

An Open, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-7058 in Patients With Locally Advanced or Metastatic Pancreatic Cancer Harboring KRAS G12C Mutations Who Have Failed Prior Systemic Therapy.

Last checked: Nov 20, 2026Latest source record: Jun 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

92

Planned (sponsor's estimate)

Start

Jun 4, 2026

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
May 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, single-arm, phase II cilinical trial designed to evaluate the efficacy and safety of the KRAS G12C selective inhibitor HRS-7058 in patients with KRAS G12C-mutated advanced pancreatic cancer who had failed 1-2 lines of previous systemic therapy.

Conditions

  • Pancreatic Cancer

Interventions

  • HRS-7058Drug

    HRS-7058

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORR as assessed by IRCTime frame: About 2 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.